Dow slides 391 points on reports that Moderna's COVID-19 vaccine study lacked key data

· *US indexes slid in late trading on Tuesday after a report said Moderna's highly touted results from a phase-one trial of its coronavirus vaccine candidate lacked key data.*
· *It marked a reversal from the **Dow Jones industrial average's 912-point surge on Monday after Moderna reported positive results from the trial.*
·...